ETC
-
Sentil Tab. 5mg
- Ingredient
Clobazam
- Content
5mg
- Indication
1) Treatment of anxiety, tension
2) Treatment of anxiety, tension in mental retardation, autonomic dysfunction, sleep disorder, organic mental disorder
3) Adjunctive treatment of seizures when antiepileptic drug monotherapy is ineffective at controlling seizures
-
Solian Tab. 100mg
- Ingredient
Amisulpride
- Content
100mg
- Indication
Treatment of schizophrenia
-
Solian Tab. 200mg
- Ingredient
Amisulpride
- Content
200mg
- Indication
Treatment of schizophrenia
-
Solian Tab. 400mg
- Ingredient
Amisulpride
- Content
400mg
- Indication
Treatment of schizophrenia
-
Stilnox CR Tab. 12.5mg
- Ingredient
Zolpidem Tartrate
- Content
12.5mg
- Indication
Short-term treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
-
Stilnox CR Tab. 6.25mg
- Ingredient
Zolpidem Tartrate
- Content
6.25mg
- Indication
Short-term treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
-
Stilnox Tab. 10mg
- Ingredient
Zolpidem Tartrate
- Content
10mg
- Indication
Short-term treatment of insomnia in adults
-
Strensiq
- Ingredient
Asfotase-alfa
- Content
18 mg/0.45 mL, 28 mg/0.7 mL, 40 mg/mL, or 80 mg/0.8 mL solution in single-dose vials
- Indication
Long-term enzyme replacement therapy in patients with pediatric-onset hypophosphatasia to treat the bone manifestations of the disease. Pediatric includes perinatal/infantile (0-6 months of age at the time of onset) and juvenile (6 months to 18 years of age at the time of onset).
-
Suglat®Tablet 50mg
- Ingredient
Ipragliflozin L-proline (In-house spec.) 64.3mg (50 mg as Ipragliflozin)
- Content
Light purple, round, film-coated tablet
- Indication
This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes.
– Monotherapy
– Combination therapy